RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
Recruiting · NCT05758831 · Registry updated 2026-02-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis. | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis | Recruiting | Phase 3 | 2026-02-02 | NCT05758831 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Rennes University Hospital | 89 |
23 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.